Sign In
Buy MBIO
$0.741
-0.0201 (-2.64%)
At Close: Jun 03, 2026
Mustang Bio's CAR T Cell Therapy Achieves 93% ORR, 67% CR In Mid-Stage Leukemia Trial
07:28am, Friday, 11'th Jun 2021
Mustang Bio Inc (NASDAQ: MBIO) has updated interim data from the ongoing Phase 1/2 trial evaluating MB-106 for high-risk B-cell non-Hodgkin lymphomas (B-NHL) and chronic lymphocytic leukemia (CLL).
Data presented at the European Hematology Association 2021 Virtual Congress show favorable safety profile and compelling clinical activity
Biotech Penny Stocks To Watch For June 2021
10:24am, Sunday, 06'th Jun 2021
These penny stocks are expecting to release key information this month. The post Biotech Penny Stocks To Watch For June 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS
5 Penny Stocks To Watch Right Now That Analysts Are Bullish On
09:53am, Tuesday, 18'th May 2021
Penny stocks remain volatile but these analysts have a bright outlook on these The post 5 Penny Stocks To Watch Right Now That Analysts Are Bullish On appeared first on Penny Stocks to Buy, Picks, New
BTIG Sees 260% Upside In Mustang Bio With PT of $11; Early-Stage MB-101 Starts Dosing Brain Tumor Patients
09:26am, Tuesday, 18'th May 2021
Mustang Bio Inc (NASDAQ: MBIO) and the City of Hope, an independent cancer research and treatment center, have dosed the first patient in Phase 1 trial evaluating MB-101 in patients with leptomen
Mustang Bio Reports First Quarter 2021 Financial Results and Recent Corporate Highlights
04:30pm, Friday, 14'th May 2021
WORCESTER, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in
Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at European Hematology Association 2021 Virtual Congress
12:45pm, Wednesday, 12'th May 2021
Fred Hutchinson Cancer Research Center to present updated interim data from ongoing MB-106 Phase 1/2 clinical trial Fred Hutchinson Cancer Research Center to present updated interim data from ongoing
Mustang Bio Announces FDA Acceptance of IND Application for MB-106, a CD20-Targeted CAR T Therapy
07:30am, Monday, 10'th May 2021
The Phase 1/2 multicenter study to assess the safety, tolerability and efficacy of MB-106 in patients with relapsed or refractory CD20+ B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia is
Mustang Bio Reports Full-Year 2020 Financial Results and Recent Corporate Highlights
04:30pm, Wednesday, 24'th Mar 2021
NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell a
Mustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day®
08:00am, Friday, 26'th Feb 2021
WORCESTER, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in
7 Penny Stocks That Actually Have Buy Ratings
01:22pm, Wednesday, 03'rd Feb 2021
Many penny stocks are destined to fail, but these seven penny stocks may succeed. Wall Street has buy recommedations on them.
Why Mustang Bio, Phathom Pharma And More Are Moving Today
11:37am, Tuesday, 02'nd Feb 2021
Mustang Bio (NASDAQ: MBIO) shares are trading higher after the company announced the FDA has lifted the clinical hold for its pivotal phase 2 MB-107 clinical trial. The company plans to enroll the fir
FDA removes clinical hold for pivotal Phase 2 MB-107 clinical trial
7 Best Penny Stocks to Buy Early Into 2021
05:16am, Tuesday, 19'th Jan 2021
Penny stocks are cheap for a reason, as there are obvious flaws. However, with those flows comes opportunity.
Mustang Bio to Participate in Three January 2021 Virtual Investor Conferences
08:30am, Tuesday, 05'th Jan 2021
WORCESTER, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in
